

Oxytocin supports the barrier integrity of brain endothelial cells via oxytocin receptors

Camilla Paolini^{1,2,3} | Francesca Piacentini^{1,2,3}  | Sarah Amato^{1,3} |
Marta Busnelli^{1,3}  | Bice Chini^{1,3}

¹Institute of Neuroscience, National Research Council (CNR), Vedano al Lambro, Monza and Brianza, Italy

²University of Milano-Bicocca, Milan, Italy

³NeuroMI Milan Center for Neuroscience, Milan, Italy

Correspondence

Marta Busnelli and Bice Chini, Institute of Neuroscience, National Research Council (CNR), Vedano al Lambro, Monza and Brianza, Italy.

Email: marta.busnelli@cnr.it and bice.chini@cnr.it

Funding information

Fondazione Telethon, Grant/Award Number: GGP19103; Fondation Jérôme Lejeune, Grant/Award Number: GRT#2109; Italian Ministry of University and Research, Grant/Award Numbers: PRIN2022-2022YJSMBX, PRIN2022-2022JLA3EA

Abstract

Oxytocin plays an emerging role in vascular regulation and neuroprotection, but its effect on brain endothelial cells and blood–brain barrier functionality is not fully defined. To assess oxytocin and vasopressin receptor expression in brain endothelial cells and to evaluate the impact of oxytocin on endothelial barrier integrity under physiological (normoxic) and low-oxygen (hypoxic) conditions we used bEnd.3 brain endothelial cells. Receptor expression was evaluated by real-time PCR and RNA-scope. Oxytocin treatment was applied under normoxic and hypoxic conditions and Transendothelial Electrical Resistance and tight junction proteins expression (claudin-5, zonula occludens-1) were analyzed. Our results indicate that 1) bEnd.3 cells express oxytocin and V1a receptors. 2) Activation of the oxytocin receptor enhanced brain endothelial barrier integrity by increasing claudin-5 expression and its localization at the cell surface, without affecting zonula occludens-1. 3) Under hypoxic conditions, oxytocin preserved Transendothelial Electrical Resistance and claudin-5 expression at the cell membrane, thereby preventing endothelial barrier impairment. Our findings demonstrate that oxytocin receptor signaling enhances and preserves brain endothelial barrier function, underscoring the relevance of oxytocin in neurovascular regulation and its therapeutic potential in blood–brain barrier dysfunction.

KEYWORDS

blood brain barrier, brain endothelial cells, claudin-5, hypoxia, oxytocin

1 | INTRODUCTION

The blood–brain barrier (BBB) strictly regulates the movement of molecules from the intravascular space to the brain interstitial compartment, playing an essential role in the health and proper function of the central nervous system.^{1,2} The anatomical basis of the BBB

consists of non-fenestrated capillaries, also known as microvessels, whose lumen is lined by highly specialized brain endothelial cells, interconnected through a complex network of junctional proteins, including tight junctions, adherens junctions, and gap junctions.^{3,4} Endothelial cells are supported by a basement membrane, pericytes, and the endfeet of astrocytes, together forming the neurovascular unit, which maintains CNS homeostasis and regulates molecular exchange.⁵ BBB dysfunction has been observed in various

Camilla Paolini and Francesca Piacentini have contributed equally to this study.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Journal of Neuroendocrinology* published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.

neurological and psychiatric disorders,⁶ and growing evidence suggests that alterations in the BBB play a role in the pathogenesis of brain diseases.^{7,8}

Hypoxia is a common stressor associated with BBB dysfunction across several medical conditions, including preterm birth, ischemic stroke, traumatic brain injury, neurodevelopmental and neurodegenerative disorders.^{9–11} Endothelial tight junctions (TJs) are essential for maintaining BBB integrity and selective permeability. Hypoxic and ischemia/reperfusion insults disrupt TJ structure and function, leading to increased BBB permeability. Studies on brain endothelial cells exposed to hypoxia have shown delocalization of TJ proteins, particularly claudin-5, a key component of BBB.¹² These changes are largely driven by hypoxia-induced transcription factors (HIFs) and partly mediated by increased vascular endothelial growth factor (VEGF) secretion.^{13,14} Pericyte-conditioned media can counteract these effects by stabilizing claudin-5 expression,¹⁵ while autophagy appears to limit hypoxia-induced BBB injury by regulating claudin-5 redistribution and degradation.¹⁶ In clinical practice, interventions to prevent or limit hypoxic brain damage involve a combination of strategies—including lung-protective ventilation, intracranial pressure control, therapeutic hypothermia, and hyperbaric oxygen therapy—but their success is limited. More clinical and basic research is needed to identify ways to mitigate anoxic and hypoxic brain injury.^{17,18}

The neuropeptide oxytocin (OT), best known for its role in parturition and lactation, plays a multifaceted role in brain function, particularly in social behavior and emotional processing.¹⁹ OT acts via the oxytocin receptor (OTR), which is expressed in the brain in neurons as well as in astrocytes.²⁰ In peripheral tissues, OTRs have been described in various cell types, including vascular endothelial cells (ECs). Thibonnier et al. first demonstrated OTR expression in ECs derived from human umbilical vein (HUVEC), aorta, and pulmonary artery,²¹ later confirmed in myometrial,²² dermal, and breast tumor-associated microvascular ECs.²³ In HUVECs, OT enhances cell proliferation, migration, and vasodilation via the nitric oxide (NO) pathway,^{21,24} and promotes angiogenesis via the PI3K/AKT/eNOS pathway²⁵ and HIF-1 α activation.²⁶ In brain microvascular endothelial cells, OTR activation exerts anti-inflammatory effects by reducing oxLDL-induced monocyte adhesion.²⁷ In zebrafish, OT is essential for the formation of the neurovascular interface of the pituitary, contributing critically to endothelial morphogenesis.²⁸ These findings suggest a potential role for OT in brain angiogenesis, in the acquisition of brain-specific endothelial phenotypes, and in BBB maintenance—in addition to its well-established cardiovascular functions (reviewed in²⁹).

Supporting a key role for OT in BBB formation and maintenance, we previously showed that OT treatment restores barrier integrity in LgDel/+ mice,³⁰ a model of 22q11.2 deletion syndrome—a genetic condition associated with increased risk for schizophrenia, ADHD, and ASD, and characterized by BBB dysfunction.³¹ OT administration during the first postnatal week induced upregulation of the tight junction proteins claudin-5 and claudin-1, resulting in reduced BBB permeability, attenuated neuroinflammation, and prevention of sensorimotor and social deficits in adulthood.³⁰

To further investigate the role of OT on barrier function, we employed an in vitro model based on cultured mouse brain endothelial cells (bEnd.3). These cells are widely used to model the BBB in vitro due to their expression of TJs and their ability to form a functional barrier.^{32,33} We first showed that bEnd.3 cells express both the OTR and the vasopressin V1a receptors (V1aR), validating their suitability for studying OT-mediated effects on brain endothelial cells. We demonstrated that OT, acting specifically through oxytocin receptors, promotes the formation of a tighter and less permeable endothelial monolayer. This effect is accompanied by increased claudin-5 expression at the cell membrane, without affecting the expression of zonula occludens-1 (ZO-1), another key tight-junction protein. Finally, we showed that OT treatment can prevent the structural and functional damage of the bEnd.3 monolayer following 48 h of hypoxic exposure, indicating a protective role for OT under hypoxic/ischemic conditions.

2 | METHODS

2.1 | Cell cultures

Brain-derived endothelial cells (bEnd.3) (ATCC cat.# CRL-2299), kindly provided by F. Papaleo (IIT, Genova, Italy), were cultured in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal bovine serum (Euroclone), 100 U/mL penicillin, 100 μ g/mL streptomycin (Euroclone), and 2 mM L-glutamine (Euroclone), in a humidified incubator at 37°C with 5% CO₂ and 95% air.

2.2 | Transendothelial electrical resistance (TEER)

Cells were seeded (20,000 cells/cm²) on ThinCert transwell inserts (Greiner Bio-One, 0.4 μ m pore, 0.336 cm² area) and starting from day 3, cells were treated every 24 h with OT (Bachem) 100 nM dissolved in DMEM or with DMEM. The selective OTR antagonist desGly-NH₂, d(CH₂)₅¹, DTyr², Ile³, Thr⁴, Asn⁵, Cys⁶, Pro⁷, Orn⁸ was used at a final concentration of 1 μ M dissolved in DMEM.³⁴ Cells were maintained for 10 days and TEER was measured every day between day 3 and day 10 using an STX-2 chopstick electrode connected to an EVOM2 volt-ohmmeter (World Precision Instruments). Three measurements were taken per insert ($n = 3–5$ per condition); values ($\Omega \cdot \text{cm}^2$) were calculated as: TEER = (mean sample resistance – mean filter resistance) \times filter area.

2.3 | Permeability assay

On day 10, after TEER measurement, cells were washed with PBS and 150 μ L of Lucifer Yellow (23 μ g/mL in DMEM, Merck) was added to the apical ('luminal') side of the endothelial cells. Briefly, 50 μ L samples were removed from the basal chamber and replaced with fresh medium at 20 min intervals for 60 min. Sample fluorescence intensity

was measured using a microplate reader (Tecan Infinite F500; exc. 400 ± 20 nm/em. 535 ± 25 nm). LY concentrations were determined by interpolation in a LY standard curve. Apparent permeability (Papp, cm/min) was calculated as:

$$1/P_{app} = 1/P_{cells} - 1/P_{filter}$$

where P_{cells} and P_{filter} are calculated as follows:

$$P = Q_{bottom} / (C_{apical} \times \Delta t \times A)$$

Q is the amount of LY passed through the monolayer; C is the concentration of the pulse; A is the insert area; Δt is the interval time.

2.4 | Real-time PCR

Total RNA was extracted from cells using the Quick-RNA MicroPrep Kit (Zymo Research). RNA purity and concentration were determined by Nano-drop One (Thermo Fisher). cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was analyzed using TaqMan probes for OTR (Mm01182684_m1), V1aR (Mm00444092_m1), V1bR (Mm01700416_m1), V2R (Mm00517071_m1), and GAPDH (Mm99999915_g1). Reactions (10 μ L) were run in triplicate using the QuantStudio 7 system (Thermo Fisher). The $\Delta\Delta Ct$ method ($2^{-\Delta\Delta Ct}$) was used for quantification.

2.5 | RNAscope in situ hybridization combined to immunofluorescence

In situ detection of oxytocin receptor (OTR) mRNA was performed using the RNAscope™ Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics, ACD), according to the manufacturer's instructions.

Briefly, bEnd.3 cells were fixed 3 days after seeding with 4% paraformaldehyde for 20 min at room temperature (RT), followed by dehydration and rehydration through a graded ethanol series (50%, 70%, and 100%). Cells were permeabilized with RNAscope Protease Plus (ACD), diluted 1:15 in PBS, for 10 min at RT. Hybridization was then performed for 2 h at 40°C using specific RNA probes for OTR, POLR2A (positive control), and dapB (negative control) (ACD). Signal amplification was carried out using AMP1, AMP2, and AMP3 reagents (ACD), followed by pre-incubation with HRP-C1 and fluorescent signal development using TSA Vivid™ 520 (Tocris) for 30 min at 40°C. The reaction was terminated using the HRP blocker provided by the manufacturer.

Following RNAscope labeling, cells were incubated overnight at 4°C with an anti-CD31 primary antibody (Abcam, ab222783; 1:200) diluted in PBS containing 5% BSA and 0.1% Triton X-100. An Alexa Fluor 568-conjugated goat anti-rabbit secondary antibody (1:400) was applied for 1 h at RT. Nuclei were counterstained with DAPI, and samples were mounted with Mowiol.

Representative images were acquired using a Zeiss LSM 800 META confocal microscope equipped with a C Plan-Apochromat 40 \times /1.3 Oil DIC M27 objective, using ZEN 2.3 (blue edition) software. Image processing was performed with Fiji/ImageJ software (version 1.54f, NIH).

OTR mRNA expression was quantified using a semi-quantitative scoring method according to the RNAscope data analysis guideline (Advanced Cell Diagnostics). The number of mRNA dots per cell was classified as follows: score 0, no staining or <1 dot per cell; score 1, 1–3 dots per cell; score 2, 4–9 dots per cell; score 3, >10 dots per cell, as described.³⁵

2.6 | Immunofluorescence and confocal imaging

Cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.3% Triton X-100, and blocked with 5% BSA and 5% NGS for 2.5 h RT. Primary antibodies (anti-claudin-5 Invitrogen 352500 1:200, anti-ZO-1 Invitrogen 61-7300 1:120, anti-CD31 Abcam 222783 1:400) were applied overnight at 4°C. Secondary antibodies (Alexa 488 goat anti-mouse, 1:1000; Alexa 568 goat anti-rabbit, 1:400) were applied for 1 h at RT, followed by DAPI staining and mounted with Mowiol. Images were acquired with Zeiss LSM 800 META confocal microscope, using a C Plan-Apochromat 40 \times /1.3 Oil DIC M27 with ZEN 2.3 (blue edition) software. Images were processed with Fiji Image J software version 1.54f (NIH Bethesda). Mean fluorescence intensity was quantified and the fluorescence density at the plasma membrane was calculated by measuring the fluorescence intensity at the plasma membrane where the two TJ proteins claudin-5 and ZO-1 are colocalized and dividing it by the membrane segment length.

2.7 | Immunoblotting

Cell lysates from bEnd.3 were prepared on days 3 and 10 in ice-cold homogenization buffer (250 mM sucrose, 1 mM MgAc, 10 mM HEPES, 1 mM EDTA, pH adjusted to 7.4 with 1 M KOH) with protease inhibitors (Merck). Protein concentration was determined using the DC Protein Assay (Bio-Rad). Protein were separated by SDS-PAGE and transferred to a 0.2 μ m nitrocellulose membrane (GE Healthcare). Membranes were blocked for 1 h in TBS containing 0.1% Tween-20 and 5% non-fat milk and incubated overnight at 4°C with primary antibodies: anti-claudin-5 (1:1000, mouse, Invitrogen) and anti-GAPDH (1:15000, rabbit, Invitrogen) diluted in TBS containing 0.1% Tween-20 and 5% non-fat milk. Membranes were washed twice with TBS containing 0.1% Tween-20 and then incubated with goat anti-mouse and goat anti-rabbit near IR-conjugated secondary antibodies (1:15000, Cyanagen) diluted in TBS containing 0.1% Tween-20 and 5% non-fat milk. Membranes were imaged using a LI-COR Odyssey Clx imaging system. Protein band fluorescence intensity was quantified using Fiji-ImageJ software and normalized to GAPDH signal from the same sample. Three independent experiments were performed.

2.8 | Hypoxia experiments

For hypoxia experiments, cells were grown until TEER values reached 25–30 $\Omega\cdot\text{cm}^2$, then transferred to a hypoxia chamber (Stemcell Technologies) and maintained at 1% O_2 for 48 h at 37°C. Cells were treated with 100 nM OT immediately prior to hypoxia and during the 2 days post-hypoxia period. TEER was recorded immediately after hypoxia and during the subsequent 2 days.

2.9 | Statistical analysis

All statistical analyses were performed using the GraphPad Prism 9 software (GraphPad Software). Two-tailed Student's *t*-test or one-way ANOVA followed by Tukey's post-hoc test for multiple comparisons were used to compare treatments or time or treatment \times conditions respectively. Two-way ANOVA followed by Holm-Šidák's multiple comparisons post-hoc test was applied to account and correct for multiple testing for the combined analysis of time and treatment or time and oxygen levels. Data are expressed as mean \pm SEM. Differences were considered statistically significant at $p < .05$.

3 | RESULTS

3.1 | OT promotes the sealing of brain endothelial cells monolayer

We first tested the ability of bEnd.3 cells to form a tight endothelial monolayer by measuring TEER daily from day 3 to day 10 post-seeding. TEER values progressively increased over time, reaching a plateau on day 6 ($32.87 \pm 1.25 \Omega\cdot\text{cm}^2$; Figure S1A), consistent with

previously reported data.^{36,37} From day 6 onward, TEER values remained stable, indicating the establishment of a steady-state barrier.

To investigate the effect of OT on brain endothelial cell barrier function, bEnd.3 cells were treated daily with 100 nM OT (Figure 1A). The effect of OT treatment on bEnd.3 monolayer properties over time was assessed using a two-way repeated-measures ANOVA with time and treatment as factors. The analysis revealed a strong main effect of time, $F(3.688, 66.03) = 74.79$, $p < .0001$, indicating a significant temporal evolution of the measured parameter. Importantly, a significant interaction between time and treatment was observed $F(7,126) = 2.09$, $p = .0492$. A direct comparison of treatments at day 10 (Figure 1B) indicated a significant increase of TEER values in OT-treated cells (Day 10: +14.3%, $p < .05$). Overall these results indicate that OT significantly influences the temporal dynamics of bEnd.3 monolayer properties, consistent with our previous findings where OT seals primary brain endothelial cells monolayer.³⁰

To determine whether this increase in TEER corresponded to reduced monolayer permeability, we measured the paracellular flux of Lucifer Yellow (LY), a small fluorescent hydrophilic fluorescent tracer. As shown in Figure 1C, OT treatment significantly decreased LY trans monolayer passage on day 10 (-23.8% , $p < .01$), further supporting an OT-mediated strengthening of the barrier.

We next examined the expression of the OTR and the three AVP receptor subtypes (V1aR, V1bR, and V2R), which can bind OT and AVP with varying affinities.³⁴ By real-time PCR analysis, we detected transcripts for OTR and V1aR, although ~ 4 times less abundant than OTR, while transcripts for V1bR and V2R were not detected (Figure S1B). OTR mRNA expression was confirmed by RNAscope in situ hybridization using probes specific for murine OTR transcripts (Figure S1C,D). Our results indicate that approximately 60% of cells were classified as RNAscope score 1 (1–3 dots per cell), while about 25% of cells were assigned to score 2 (4–9 dots per cell). As each RNAscope dot corresponds to a single mRNA molecule, these scores





FIGURE 1 OT promotes the formation of a sealed brain endothelial cells monolayer. (A) Transendothelial electric resistance (TEER) of bEnd.3 during the differentiation of the cell monolayer is shown. Cells were seeded on transwell and starting from day 3 treated with OT 100 nM or not-treated (NT). Fold increase was calculated as TEER on day X/TEER on day 3 ($n = 10/\text{group}$). Data are shown as mean \pm SEM, two-way ANOVA followed by Holm-Šidák's multiple comparisons post-hoc test $*p < .05$. (B) bEnd.3 fold increase TEER values on day 10 of untreated and OT treated cells. ($n = 10/\text{group}$). (C) LY permeability of untreated and OT (100 nM) treated cell monolayer was measured on day 10 in cm/min ($n = 8/\text{group}$). Data are shown as mean \pm SEM, Student's *t*-test $**p < .01$. (D) In another set of experiments TEER was measured in bEnd.3 cells treated from day 7 post-seeding with DMEM (NT), OT 100 nM (OT) or OT 100 nM in the presence of a selective OTR antagonist (OTA + OT). TEER fold increase was calculated as TEER on day 7, 8, 9 or 10/TEER on day 3. Graph is representative of one of three independent experiments each performed in triplicate. Data are shown as mean \pm SEM, two-way ANOVA $**p < .01$; $*p < .05$.

FIGURE 2 Claudin-5 and ZO-1 expression and plasma membrane localization on day 3 and day 10 post seeding. (A) bEnd.3 cells were stained on day 3 and day 10 post-seeding with DAPI (blue), and with specific antibodies for zonula occludens-1 (ZO-1, red) and for claudin-5 (CLDN5, green). The merge of the different color channels is reported. Scale bar = 20 μ m. (B) Quantification of CLDN5 and (C) ZO-1 total mean fluorescence intensity on day 3 and on day 10 post-seeding. Images from two independent experiments, each performed in triplicate, were analyzed. Dots represent the average value from five fields randomly taken from each slide. (D) CLDN5 and GAPDH (used as control) expression was determined by western blotting in bEnd.3 cells on day 3 and on day 10 post-seeding. (E) Quantification of total CLDN5 normalized on GAPDH of untreated bEnd.3 on day 3 and on day 10. Three independent experiments have been performed, and each dot represents the quantification of a single experiment. Data are shown as mean \pm SEM, Student's *t*-test **p* < .05, ****p* < .001.



indicate low and moderate levels of OTR expression, respectively, according to ACD RNAscope guidelines. In conclusion, real-time PCR data and RNAscope scoring revealed that OTR mRNA is expressed at medium-to-low levels in bEnd.3 cells (Figure S1).

To evaluate the specific contribution of OTR to OT-mediated modulation of bEnd.3 monolayer properties, cells were treated with OT (100 nM) from day 3 after seeding, in the presence of the selective OTR antagonist desGly-NH₂, d(CH₂)₅¹, DTyr², Ile³, Thr⁴, Asn⁵, Cys⁶, Pro⁷, Orn⁸ (1 μ M), whose affinity for murine OTR is 1.24 nM and for V1aR is >10,000 nM.³⁴ Pre-incubation with the antagonist abolished the OT-induced TEER increase measured at day 7, 8, 9 and 10 after seeding, indicating that these responses are mediated through OTR activation (Figure 1D).

3.2 | OT treatment promotes claudin-5 localization at the plasma membrane

To evaluate the maturation of tight junctions in bEnd.3 monolayers, we analyzed the expression and localization of claudin-5 and ZO-1 on days

3 and 10 post-seeding (Figure 2A). As shown in Figure 2B,C, both TJ proteins exhibited significantly higher expression on day 10 compared to day 3 (claudin-5: +219%, *p* < .05; ZO-1: +62.6%, *p* < .05), consistent with a progressive monolayer maturation as previously reported.^{32,33,38,39} This upregulation was accompanied by increased accumulation of both proteins at the cell outlines, indicative of their localization to membrane-associated TJ structures. Claudin-5 upregulation was further confirmed by Western blotting analysis, showing a 221.2% increase on day 10 relative to day 3 (*p* = .001; Figure 2D, E).

Given our previous observations that OT enhances claudin-5 expression in brain primary endothelial cells,³⁰ we next examined whether OT similarly affects TJ protein levels in bEnd.3 cells. As shown in Figure 3, neither claudin-5 nor ZO-1 total protein levels were significantly altered by OT treatment, as determined by both immunofluorescence (Figure 3B,C) and Western Blotting (Figure 3D,E). However, considering that claudin-5 exerts its barrier functions specifically at the plasma membrane forming tight junctions, we quantified its localization at the cell outline. OT treatment significantly increased claudin-5 density at the cell outline compared to untreated controls (+36.3%, *p* < .05,




FIGURE 3 OT treatment specifically promotes claudin-5 localization at the plasma membrane. (A) bEnd.3 cells were treated from day 3 to day 10 post seeding with OT (100 nM) or not treated (NT) and on day 10 were stained with DAPI (blue), and with specific antibodies for zonula occludens-1 (ZO-1, red) and for claudin-5 (CLDN5, green). The merge of the different color channels is reported. Scale bar = 20 μ m. (B) Quantification of CLDN5 and (C) ZO-1 total mean fluorescence intensity of untreated and OT treated cells on day 10. Images from two independent experiments, each performed in triplicate, were analyzed. Dots represent the average value from five fields randomly taken from each slide. (D) CLDN5 and GAPDH (used as control) expression was determined by western blotting in bEnd.3 cells on day 10 in not treated cells (NT) and OT (100 nM) treated cells and on day 10 post-seeding (E) Quantification of total CLDN5 normalized on GAPDH of not-treated (NT) and OT-treated (OT) cells on day10. Three independent experiments have been performed, and each dot represents the quantification of a single experiment. (F) Scheme of the Tight junction composition: claudin- 5 (CLDN5) in green; zonula occludens (ZO) protein-1, 2 and 3 (ZO-1, ZO-2, ZO-3) in shades of light blue; Junctional Adhesion Molecule 1 (JAM-1) in pink; Actin in camel. Illustration was made with bioart.niaid.nih.gov and Microsoft Power Point. (G) Quantification of ZO-1 and (H) CLDN5 fluorescence density at the cell membrane in untreated and OT treated cells on day10. Images from two independent experiments, each performed at least in triplicate, were analyzed. Dots represent the average value from five fields randomly taken from each slide. Data are shown as mean \pm SEM, Student's *t*-test, **p* < .05.




FIGURE 4 OT treatment protects against functional BBB dysfunction induced by hypoxia. (A) Experimental scheme of the hypoxia protocol on bEnd.3-3 cells. Cells were grown until Transendothelial electrical resistance (TEER) measurements reached 25–30 $\Omega \cdot \text{cm}^2$, then (Day 0–Day 2) for the Hypoxia condition cells were inserted in a hypoxic chamber (1% O₂) or for the control maintained with (19% O₂) (Normoxia). Day 2–Day 4, cells were maintained with 19% O₂. For the Hypoxia+ OT conditions between Day 0 and Day 3 cells were treated with OT (100 nM). Transendothelial electrical resistance (TEER) measurements were performed on Day 2, Day 3 and Day 4. Normalized TEER was obtained by the ratio of TEER measurement on the day before the start of the hypoxia protocol. Data are shown as mean \pm SEM, two-way ANOVA-test **** $p < .001$ ($n = 9$ /condition). Graph is representative of one of two independent experiments. (B) Transendothelial electrical resistance (TEER) measurements on Day 4 of bEnd.-3 cells under normoxic, hypoxic and hypoxic+ OT (100 nM) treatment. Normalized TEER was obtained by the ratio of TEER measurement on the second day after the end of hypoxia treatment (Day 4) and the measurement on the day before the start of the hypoxia protocol (Day 0). Data are shown as mean \pm SEM, one-way ANOVA *** $p < .001$ ($n = 9$ /condition).

Figure 3H). This effect was selective for claudin-5, as ZO-1 localization at the cell border was not significantly affected by OT ($p = .66$ Figure 3G).

These findings indicate that OT enhances the functional organization of TJs by promoting the membrane localization of claudin-5, without altering its overall intracellular expression.

3.3 | OT treatment protects against functional and structural BBB dysfunction induced by hypoxia

Given that OT enhanced endothelial monolayer sealing and promoted claudin-5 membrane localization, we investigated whether OT could

protect brain endothelial cells from hypoxia—a well-established disruptor of BBB integrity.¹⁵

To assess the impact of oxygen deprivation on barrier function, bEnd.3 monolayers were exposed to hypoxic conditions (1% O₂) for 48 h. TEER was measured immediately after hypoxia as well as 24 and 48 h after reoxygenation. The effects of oxygen condition on endothelial barrier properties over time were analyzed using a two-way repeated-measures ANOVA with time and oxygen as factors (Figure 4A). The analysis revealed a highly significant interaction between time and oxygen ($F(2,32) = 168.6$, $p < .0001$). A significant main effect of time was also observed ($F(2,32) = 21.23$, $p < .0001$), reflecting dynamic changes in normalized TEER across the experimental period. Post hoc comparisons showed that hypoxia significantly increased normalized TEER at day 2 and decreased normalized TEER at day 4 compared to normoxia ($p < .0001$), whereas no significant difference was detected at day 3. Notably, this transient and seemingly paradoxical hypoxia-induced increase in TEER has been previously reported.⁴⁰

Importantly, OT treatment administered throughout the hypoxic exposure and subsequent 48-h recovery period effectively preserved TEER levels ($p = .1825$ vs. normoxic control, Figure 4B), suggesting that OT protects endothelial monolayer integrity under hypoxic stress.

To explore the structural correlates of this functional protection, we evaluated the expression of claudin-5 and ZO-1 following hypoxia (Figure 5A). ZO-1 total protein expression and its expression at the cell membrane were not significantly affected by hypoxia ($p = .8788$ and $p = .4989$, respectively; Figure 5B–D). In contrast, hypoxia significantly reduced both total claudin-5 expression (-31.19% , $p < .01$) and claudin-5 expression at the plasma membrane (-48.33% ; $p < .0001$; Figure 5C–E). Strikingly, OT treatment prevented this hypoxia-induced loss of claudin-5, preserving both its total protein levels and cell membrane localization.

These results support a protective role for OT in maintaining BBB integrity under hypoxic conditions through stabilization of claudin-5 expression and localization at the endothelial cell surface.

4 | DISCUSSION

We used the bEnd.3 cell line to study the effects of OT on brain endothelial cell function. Originally isolated from mouse brain endothelioma, bEnd.3 cells are widely used to investigate the barrier function of brain endothelial cells, due to their ability to form a tight monolayer characterized by a measurable TEER and low permeability to small molecules. The development of barrier function in bEnd.3 cells is supported by TJs formation, marked by the progressive expression and membrane localization of claudin-5 and ZO-1, as the cells reach confluence. In our study, bEnd.3 cells achieved TEER values and permeability levels for small fluorescent molecules consistent with those previously reported for this model.^{36,37} Furthermore, in agreement with earlier findings,^{32,33,38,39} both ZO-1 and claudin-5 levels increased by day 10 post-seeding, indicating the establishment of a mature and functionally competent endothelial barrier.




FIGURE 5 OT treatment protects against structural BBB dysfunction induced by hypoxia. Cells were grown until they form a tight monolayer (Transendothelial electrical resistance measurements values 25–30 Ω ·cm²) and then (Day 0–Day 2) were maintained in hypoxic conditions (1% O₂) or normoxic conditions (19% O₂). Day 2–Day 4, cells were maintained with 19% O₂. For the Hypoxia+ OT conditions between Day 0 and Day 3 cells were treated with OT (100 nM). (A) Cell staining of bEnd.3 cells was done on Day 4 with DAPI (blue), claudin-5 (CLDN5, green), zonula occludens-1 (ZO-1, red). The merge of the different color channels is represented. Scale bar = 20 μm. (B–D) Quantification of ZO-1 and CLDN5 total mean fluorescence intensity and (C–E) ZO-1 and CLDN5 fluorescence density at the cell membrane. Images from two independent experiments, each performed in quadruplicate, were analyzed. Dots represent the average value from five fields randomly taken from each slide. Data are shown as mean ± SEM, Statistical analysis was performed using one-way ANOVA multiple comparison followed by Tukey's post hoc test for multiple comparison. ***p* < .01, *****p* < .0001.

In this study, we provide the first evidence that the mouse brain endothelial cell line bEnd.3 expresses both OTR and V1a receptors. This finding aligns with previous reports of OTR expression in human brain microvascular endothelial cells.^{27,30} While V1aR has been identified in peripheral endothelial cells, where it may counteract barrier hyperpermeability,⁴¹ its expression within the brain vasculature appears to be limited, being detected primarily in the choroid plexus, extra parenchymal vessels, and only sporadically in intraparenchymal capillaries.⁴² Further studies are warranted to clarify the spatial distribution and functional role of V1aR in brain endothelial cells. From a

pharmacological standpoint, distinguishing the specific contributions of OTR and V1aR when they are co-expressed in the same cellular context is challenging, as both receptors can be activated by OT—albeit at different concentrations.³⁴ To rule out a functional role for V1a receptors in bEnd.3 barrier formation, we employed a selective OTR antagonist at a concentration known to specifically block OTR without affecting V1aR.³⁴ TEER measurement demonstrated that the effect of OT was abolished in the presence of the OTR antagonist, indicating a specific role for OTR. These findings are significant as they validate bEnd.3 cells as an in vitro model to study OTR-driven

mechanisms regulating brain endothelial cells barrier formation under physiological and pathophysiological conditions.

We found that OT chronic treatment enhances the integrity of the endothelial monolayer by promoting the specific membrane localization of claudin-5. These results are consistent with our previous observation in primary endothelial brain cultures, where we observed claudin-5 accumulation at the cell membrane with OT treatment.³⁰ However, the selective effect of OTR activation on claudin-5 warrants further investigation to elucidate the underlying intracellular signaling pathways involved. One possible explanation lies in a recent study highlighting the role of Wnt/ β -catenin signaling in TJ regulation; activation of this pathway—positively regulated by specific microRNAs—was shown to enhance membrane localization of claudin-5 and occludin, but not ZO-1.⁴³ The critical role of claudin-5 in establishing endothelial barrier properties is further supported by RNA interference experiments, in which claudin-5 knockdown impaired the TEER increase of confluent bEnd.3 monolayers.³⁸ Interestingly, hypoxia altered the location of claudin-5 in the plasma membrane and the level of claudin-5 protein in bEnd.3 cells, and these changes were accompanied by a decrease in TEER.³⁸

These findings prompted us to investigate the potential protective role of OT in bEnd.3 cells under hypoxic conditions. Our results show that OT administration during and immediately after hypoxia effectively restored TEER values to baseline, indicating a protective effect on monolayer integrity. In parallel, OT treatment also prevented the hypoxia-induced loss of claudin-5, restoring both its total protein levels and junctional localization. These results highlight OT's potential to prevent hypoxia-induced blood–brain barrier alterations in ischemia–reperfusion injury.

At the mechanistic level, we observed that hypoxia reduced claudin-5 expression at the plasma membrane, while ZO-1 levels remained unaffected. This selective vulnerability of claudin-5 is consistent with previous studies in bEnd.3 cells exposed to oxygen and glucose deprivation.^{44,45} The functional relevance of claudin-5 down-regulation is underscored by the parallel decrease in TEER, a finding in agreement with reports in human brain microvascular endothelial cells under similar hypoxic conditions.¹⁵

Beyond Wnt/ β -catenin signaling, which may contribute to claudin-5 membrane localization, other OT-regulated protective pathways could be involved. Notably, hypoxia is known to induce the metalloprotease MMP-9, which degrades the neurovascular extracellular matrix and disrupts tight junctions, thereby compromising BBB integrity.⁴⁶ OT has been shown to reduce MMP-9 expression in the cortex and hippocampus after cerebral ischemia in mice,⁴⁷ suggesting that MMP inhibition may be one of the mechanisms underlying its protective effect. Additionally, metabolic dysregulation during hypoxia/ischemia may contribute to BBB breakdown.⁴⁸ Interestingly, OT has been reported to enhance glucose uptake in cardiomyocytes under both normoxic and hypoxic conditions,⁴⁹ raising the possibility that it may support endothelial energy metabolism as well.

In conclusion, our findings confirm that OT directly promotes brain endothelial barrier formation through OTR expressed on endothelial cells, specifically by enhancing claudin-5 expression and its

localization at the cell surface. Importantly, OT treatment also protects the endothelial monolayer under hypoxic stress, highlighting OT's potential as a therapeutic agent for blood–brain barrier preservation and neurovascular repair.

AUTHOR CONTRIBUTIONS

Camilla Paolini: investigation; methodology; data analysis; manuscript writing; **Francesca Piacentini:** investigation; methodology; data analysis; manuscript writing; **Sarah Amato:** investigation; data analysis; **Marta Busnelli:** conceptualization; funding acquisition; manuscript writing; project administration; supervision; **Bice Chini:** conceptualization; funding acquisition; manuscript writing; project administration; supervision. All the authors revised the manuscript.

ACKNOWLEDGMENTS

We thank Dalila Barraco and Gloria Fretto for technical support. Open access publishing facilitated by Consiglio Nazionale delle Ricerche, as part of the Wiley - CRUI-CARE agreement.

FUNDING INFORMATION

This study was supported by funding from Fondazione Telethon Italia (project n. GGP19103) to Bice Chini; the Jerome Lejeune Foundation (“Role of neuropeptides on Blood Brain Barrier formation and maintenance in a 22q11.2DS mouse model”) to Bice Chini. This study was also supported by National Recovery and Resilience Plan (NRRP), Mission 4-Component 2-Investment 1.1-Call for tender No. 104 published on 2.2.2022 by the Italian Ministry of University and Research (MUR), funded by the European Union—Next Generation EU—PRIN2022-2022YJSMBX—CUP B53D23006320006 to Marta Busnelli and PRIN2022-2022JLA3EA-CUP B53D23018700006 to Bice Chini.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no competing interests.

PEER REVIEW

For transparency, the peer review documents associated with this article are available at <https://doi.org/10.1111/jne70152>.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Francesca Piacentini  <https://orcid.org/0009-0007-2771-4758>

Marta Busnelli  <https://orcid.org/0000-0003-3387-2190>

REFERENCES

1. Anwar MM, Ozkan E, Gursoy-Ozdemir Y. The role of extracellular matrix alterations in mediating astrocyte damage and pericyte dysfunction in Alzheimer's disease: a comprehensive review. *Eur J Neurosci.* 2022;56:5453-5475.
2. Langen UH, Ayloo S, Gu C. Development and cell biology of the blood-brain barrier. *Annu Rev Cell Dev Biol.* 2019;35:591-613.

3. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. *Progr Drug Res Fortschritte der Arzneimittelforschung*. 2003;61:39-78.
4. Solar P, Zamani A, Lakatosova K, Joukal M. The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments. *Fluids Barr CNS*. 2022;19:29.
5. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol Rev*. 2005;57:173-185.
6. Kealy J, Greene C, Campbell M. Blood-brain barrier regulation in psychiatric disorders. *Neurosci Lett*. 2020;726:133664.
7. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. *Acta Neuropathol*. 2018;135:311-336.
8. Pong S, Karmacharya R, Sofman M, Bishop JR, Lizano P. The role of brain microvascular endothelial cell and blood-brain barrier dysfunction in schizophrenia. *Complex Psychiatry*. 2020;6:30-46.
9. Aragon-Gonzalez A, Shaw PJ, Ferraiuolo L. Blood-brain barrier disruption and its involvement in neurodevelopmental and neurodegenerative disorders. *Int J Mol Sci*. 2022;23:15271.
10. Bernardo-Castro S, Sousa JA, Bras A, et al. Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery. *Front Neurol*. 2020;11:594672.
11. Jithoo A, Penny TR, Pham Y, et al. The temporal relationship between blood-brain barrier integrity and microglial response following neonatal hypoxia ischemia. *Cells*. 2024;13:660.
12. Engelhardt S, Al-Ahmad AJ, Gassmann M, Ogunshola OO. Hypoxia selectively disrupts brain microvascular endothelial tight junction complexes through a hypoxia-inducible factor-1 (HIF-1) dependent mechanism. *J Cell Physiol*. 2014;229:1096-1105.
13. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. *Proc Natl Acad Sci U S A*. 2009;106:1977-1982.
14. Mao J, Liu J, Zhou M, Wang G, Xiong X, Deng Y. Hypoxia-induced interstitial transformation of microvascular endothelial cells by mediating HIF-1 α /VEGF signaling in systemic sclerosis. *PLoS One*. 2022;17:e0263369.
15. Jamieson JJ, Lin Y, Malloy N, Soto D, Searson PC, Gerecht S. Hypoxia-induced blood-brain barrier dysfunction is prevented by pericyte-conditioned media via attenuated actomyosin contractility and claudin-5 stabilization. *FASEB J*. 2022;36:e22331.
16. Yang Z, Lin P, Chen B, et al. Autophagy alleviates hypoxia-induced blood-brain barrier injury via regulation of CLDN5 (claudin 5). *Autophagy*. 2021;17:3048-3067.
17. Alshehri A, Ince J, Panerai RB, Divall P, Robinson TG, Minhas JS. Physiological variability during prehospital stroke care: which monitoring and interventions are used? *Health*. 2024;12:835.
18. You Q, Lan XB, Liu N, et al. Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: current status and challenges. *Eur J Pharmacol*. 2023;957:176003.
19. Rigney N, de Vries GJ, Petrusis A, Young LJ. Oxytocin, vasopressin, and social behavior: from neural circuits to clinical opportunities. *Endocrinology*. 2022;163:1-13.
20. Baudon A, Clauss Creusot E, Althammer F, Schaaf CP, Charlet A. Emerging role of astrocytes in oxytocin-mediated control of neural circuits and brain functions. *Prog Neurobiol*. 2022;217:102328.
21. Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC. Human vascular endothelial cells express oxytocin receptors. *Endocrinology*. 1999;140:1301-1309.
22. Weston GC, Cann L, Rogers PA. Myometrial microvascular endothelial cells express oxytocin receptor. *BJOG*. 2003;110:149-156.
23. Cassoni P, Marrocco T, Bussolati B, et al. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. *Mol Cancer Res*. 2006;4:351-359.
24. Cattaneo MG, Chini B, Vicentini LM. Oxytocin stimulates migration and invasion in human endothelial cells. *Br J Pharmacol*. 2008;153:728-736.
25. Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. *Exp Cell Res*. 2009;315:3210-3219.
26. Zhu J, Wang H, Zhang X, Xie Y. Regulation of angiogenic behaviors by oxytocin receptor through Gli1-induced transcription of HIF-1 α in human umbilical vein endothelial cells. *Biomed Pharmacother*. 2017;90:928-934.
27. Liu S, Pan S, Tan J, Zhao W, Liu F. Oxytocin inhibits ox-LDL-induced adhesion of monocytic THP-1 cells to human brain microvascular endothelial cells. *Toxicol Appl Pharmacol*. 2017;337:104-110.
28. Gutnick A, Blechman J, Kaslin J, et al. The hypothalamic neuropeptide oxytocin is required for formation of the neurovascular interface of the pituitary. *Dev Cell*. 2011;21:642-654.
29. McKay EC, Counts SE. Oxytocin receptor signaling in vascular function and stroke. *Front Neurosci*. 2020;14:574499.
30. Castellani G, Ciampoli M, Benedetti A, et al. Oxytocin seals the blood-brain barrier, improving 22q11.2 deletion syndrome trajectories. *Brain*. 2025;148:3184-3198.
31. Crockett AM, Ryan SK, Vasquez AH, et al. Disruption of the blood-brain barrier in 22q11.2 deletion syndrome. *Brain*. 2021;144:1351-1360.
32. Brown RC, Morris AP, O'Neil RG. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. *Brain Res*. 2007;1130:17-30.
33. Watanabe T, Dohgu S, Takata F, et al. Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND.3, bEND.5 and mouse brain endothelial cell 4. *Biol Pharm Bull*. 2013;36:492-495.
34. Busnelli M, Bulgheroni E, Manning M, Kleinau G, Chini B. Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors. *J Pharmacol Exp Ther*. 2013;346:318-327.
35. Ariotta V, Azzalini E, Canzonieri V, Hautaniemi S, Bonin S. Comparative analysis of gene expression analysis Methods for RNA in situ hybridization images. *J Mol Diagn*. 2024;26:931-942.
36. Sun J, Ou W, Han D, Paganini-Hill A, Fisher MJ, Sumbria RK. Comparative studies between the murine immortalized brain endothelial cell line (bEnd.3) and induced pluripotent stem cell-derived human brain endothelial cells for paracellular transport. *PLoS One*. 2022;17:e0268860.
37. Yang S, Mei S, Jin H, et al. Identification of two immortalized cell lines, ECv304 and bEnd3, for in vitro permeability studies of blood-brain barrier. *PLoS One*. 2017;12:e0187017.
38. Koto T, Takubo K, Ishida S, et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. *Am J Pathol*. 2007;170:1389-1397.
39. Song L, Pachter JS. Culture of murine brain microvascular endothelial cells that maintain expression and cytoskeletal association of tight junction-associated proteins. *In Vitro Cell Dev Biol*. 2003;39:313-320.
40. Ozgur B, Helms HCC, Tornabene E, Brodin B. Hypoxia increases expression of selected blood-brain barrier transporters GLUT-1, P-gp, SLC7A5 and TFRC, while maintaining barrier integrity, in brain capillary endothelial monolayers. *Fluids Barriers CNS*. 2022;19:1.
41. Barabutis N, Marinova M, Solopov P, et al. Protective mechanism of the selective vasopressin V(1A) receptor agonist selepressin against endothelial barrier dysfunction. *J Pharmacol Exp Ther*. 2020;375:286-295.
42. Ostrowski NL, Lolait SJ, Young WS 3rd. Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. *Endocrinology*. 1994;135:1511-1528.
43. Harati R, Hammad S, Tlili A, Mahfood M, Mabondzo A, Hamoudi R. miR-27a-3p regulates expression of intercellular junctions at the brain endothelium and controls the endothelial barrier permeability. *PLoS One*. 2022;17:e0262152.

44. Ku JM, Taher M, Chin KY, Grace M, McIntyre P, Miller AA. Characterisation of a mouse cerebral microvascular endothelial cell line (bEnd.3) after oxygen glucose deprivation and reoxygenation. *Clin Exp Pharmacol Physiol*. 2016;43:777-786.
45. Neuhaus W, Gaiser F, Mahringer A, Franz J, Riethmuller C, Forster C. The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier. *Front Cell Neurosci*. 2014;8:352.
46. Hu Y, Zheng Y, Wang T, Jiao L, Luo Y. VEGF, a key factor for blood brain barrier injury after cerebral ischemic stroke. *Aging Dis*. 2022;13:647-654.
47. Momenabadi S, Vafaei AA, Zahedi Khorasani M, Vakili A. Pre-ischemic oxytocin treatment alleviated neuronal injury via suppressing NF-kappaB, MMP-9, and apoptosis regulator proteins in a mice model of stroke. *Cell J*. 2022;24:337-345.
48. Vandekeere S, Dewerchin M, Carmeliet P. Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. *Microcirculation*. 2015;22:509-517.
49. Florian M, Jankowski M, Gutkowska J. Oxytocin increases glucose uptake in neonatal rat cardiomyocytes. *Endocrinology*. 2010;151:482-491.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Paolini C, Piacentini F, Amato S, Busnelli M, Chini B. Oxytocin supports the barrier integrity of brain endothelial cells via oxytocin receptors. *J Neuroendocrinol*. 2026;38(3):e70152. doi:[10.1111/jne.70152](https://doi.org/10.1111/jne.70152)